Medication info
Lirivea Capsule 150 mg (Pregabalin)

Lirivea Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
A hard capsule containing a white or light yellow powder, with a white upper part and a white lower part
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201702211 · Approved 2017.04.28 · Insurance code 694001340

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
7. Pediatric and adolescent patients Administration is not recommended for children younger than 12 years or adolescent patients aged 12 ~17 years because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures unrelated to secondary general symptoms in patients with epilepsy. Additionally, it is effective in the treatment of fibromyalgia, used to improve symptoms of various neurological-related disorders.

How to take

Adult dose

Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Method of administration Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

7. Pediatric and adolescent patients Administration is not recommended for children younger than 12 years or adolescent patients aged 12 ~17 years because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors. If depression or mood changes occur while taking it, inform medical personnel immediately. It should not be used by individuals with an allergy to any of its ingredients or certain genetic lactose intolerance diseases. Diabetes patients should be cautious, as weight gain may require adjustments in blood sugar regulating medications. If a serious allergic reaction such as angioedema occurs, stop taking the medication immediately. Elderly patients should be especially careful at the beginning of treatment due to the risk of falls caused by dizziness or drowsiness. There may be blurred vision or other vision changes; consult a healthcare professional if these symptoms occur. Sudden discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, or anxiety, so dosage should be gradually adjusted under a doctor's guidance. As there is a risk of drug abuse, patients with a history of mental health issues or drug abuse should consult healthcare professionals before taking it. Patients with impaired kidney function may need dosage adjustments for this medication. Patients with heart disease should exercise caution while taking this medication; inform medical personnel if symptoms of heart failure appear. When taken with opioid analgesics, there may be an increased central nervous system depressant effect, so caution is advised. This medication can cause dizziness and drowsiness; therefore, avoid risky activities such as driving or operating machinery until symptoms are confirmed. In early pregnancy, it may affect the fetus, so women who are pregnant or planning to become pregnant should consult healthcare professionals before taking it. Breastfeeding women should consult healthcare professionals regarding the possibility of this medication being transmitted through breast milk. In cases of overdose, symptoms such as confusion, drowsiness, and depression may occur; immediate medical attention should be sought.

Side effects

Suicidal thoughts, suicidal behaviors, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, suicidal thoughts, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, depression, relief, decreased libido, insomnia, depersonalization, hypersexuality, restlessness, agitation, mood disturbance, emotional depression, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to suppress, apathy, dizziness, drowsiness, ataxia, coordination abnormalities, balance disorders, memory loss, attention disorders, memory disorders, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, language disorders, myoclonus, decreased reflexes, movement abnormalities, psychomotor agitation, positional vertigo, hypersensitivity, burning sensation, rest tremor, syncope, confusion, hypokinesia, olfactory abnormalities, loss of taste, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, eye swelling, decreased vision, eye pain, eye fatigue, increased tear secretion, eye irritation, mydriasis, during vibration, changes in the depth of perception of vision, strabismus, brightness of vision, vertigo, auditory hyperesthesia, first-degree heart block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, shortness of breath, nosebleeds, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, swallowing difficulties, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, throat pain, muscle stiffness, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, kidney failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling drunk, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, elevated alanine aminotransferase, increased serum creatine phosphokinase, elevated aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, confusion, depression, agitation, restlessness, worsening of convulsions, gastrointestinal disorders, tinnitus, sleep disorders, skin diseases, increased BUN, bloody stools, fatigue, weakness, gait abnormalities, decreased libido, sleep disorders, insomnia, ataxia, speech disorders, sensory abnormalities, memory disorders, attention disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and maintained in a cool place between 15 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

A hard capsule containing a white or light yellow powder, with a white upper part and a white lower part

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.